X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CTO1681 cell therapy, prevents and treats Cytokine Release Syndrome by targeting the NF-kB signaling pathway via the activation of the EP4 receptor, which reduces NF-kB signaling.
Lead Product(s): CTO1681
Therapeutic Area: Immunology Product Name: CTO1681
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
CTO1681 reduces cytokines generated during CRS induced by bispecific antibodies without causing systemic off-target effects or increasing the risk of neurotoxicity like current CRS treatments.
Lead Product(s): CTO1681
Therapeutic Area: Immunology Product Name: CTO1681
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
The safety data presented in the final clinical study report supports further human clinical development of GP1681 used to treat the excessive inflammatory response triggered by many diseases and therapies.
Lead Product(s): GP1681
Therapeutic Area: Immunology Product Name: GP1681
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2021
Details:
The new clinical trial is designed to evaluate the use of GP1681 as a potential new medicine to treat the severe immune response to COVID-19.
Lead Product(s): GP1681
Therapeutic Area: Immunology Product Name: GP1681
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The funding would accelerate the development of CytoAgents' lead drug candidate, GP1681, an investigational new drug to treat “cytokine storm” induced by COVID-19, from the Richard King Mellon Foundation.
Lead Product(s): GP1681
Therapeutic Area: Immunology Product Name: GP1681
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Richard King Mellon Foundation
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Funding July 07, 2020
Details:
The Phase II SBIR grant is non-dilutive funding from the National Institute of Allergy and Infectious Diseases of the NIH and will advance the research of GP1681.
Lead Product(s): GP1681
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Funding May 13, 2020
Details:
The collaboration aims to focus on the development of GP1681 (CTO1681), which is a small molecule inhibitor of cytokine release targeting the NF-kB signaling pathway via the activation of the EP4 receptor. It is under development for treatment of cytokine release syndrome.
Lead Product(s): CTO1681
Therapeutic Area: Immunology Product Name: GP1681
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Quotient Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
